Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Fowell

Retina Specialist Rockford, IL Medical Doctor

NPI 1821091075 CMS profile 309049

1235 N Mulford Rd, Suite 100, Rockford, IL 61107

Open in the dashboard

General payments

$2,196

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Fowell of Rockford, IL is reported in the CMS Open Payments database as having received $2,196 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $315 12
2024 General $387 12
2023 General $331 13
2022 General $162 7
2021 General $325 19
2020 General $340 15
2019 General $337 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Fowell
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Susan Fowell were reported at $315. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Susan Fowell Retina Specialist median Middle half National median
2019 $337 $410 $157–$1,517 $163
2020 $340 $168 $65–$778 $114
2021 $325 $258 $101–$1,161 $132
2022 $162 $418 $162–$1,488 $149
2023 $331 $476 $178–$1,312 $160
2024 $387 $520 $188–$1,372 $164
2025 $315 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $770 21 payments
  2. Genentech USA, Inc. $578 27 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $303 20 payments
  4. Apellis Pharmaceuticals, Inc. $181 9 payments
  5. Novartis Pharmaceuticals Corporation $130 7 payments
  6. Optos, Inc. $52 3 payments
  7. Allergan Inc. $43 3 payments
  8. Coherus Biosciences Inc. $40 1 payment
  9. Astellas Pharma US Inc $38 2 payments
  10. Sun Pharmaceutical Industries Inc. $23 1 payment
  11. Other $37 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,160 94 payments
  2. Gift $19 1 payment
  3. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. EYLEA $524 16 payments
  2. VABYSMO $424 18 payments
  3. EYLEA HD $368 9 payments
  4. LOTEMAX SM $263 18 payments
  5. PROLENSA $191 12 payments
  6. Syfovre $181 9 payments
  7. Lucentis $145 8 payments
  8. BEOVU $130 7 payments
  9. P200DTx $52 3 payments
  10. P200T $52 3 payments
  11. Other $392 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,359

Median for Ophthalmology: 891

Drug cost

$377,252

Median for Ophthalmology: $68,233

Branded share of claims

61%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolensa Bromfenac Sodium Brand 693 $311,629
Bromfenac Sodium Generic 89 $18,969
Alphagan P Brimonidine Tartrate Brand 46 $17,475
Lumigan Bimatoprost Brand 49 $16,258
Brimonidine Tartrate Generic 32 $2,759
Travoprost Generic 20 $2,351
Prednisolone Acetate Generic 70 $2,228
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 15 $1,855
Timolol Maleate Generic 213 $1,743
Brinzolamide Generic 12 $930

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$2,910,311

Of which drugs: $2,466,829

Medicare patients

622

Average age 79

Services billed

41,538

409 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 38%
Ischemic heart disease 31%
Chronic kidney disease 30%
Heart failure 24%
Atrial fibrillation 22%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 159 2,044 $1,330,290
Injection, faricimab-svoa, 0.1 mg J2777 Office 61 30,421 $823,220
Injection, aflibercept hd, 1 mg J0177 Office 16 520 $136,893
Injection, ranibizumab, 0.1 mg J2778 Office 41 963 $116,394
Injection, bevacizumab, 10 mg J9035 Office 85 355 $19,674

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $168
$168 — 520
VABYSMO
  • Genentech USA, Inc. $84
$84 — 30,421
Syfovre
  • Apellis Pharmaceuticals, Inc. $71
$71 — —
EYLEA
  • Regeneron Healthcare Solutions, Inc. $46
$46 — 2,044
Izervay
  • Astellas Pharma US Inc $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record